Into the 7.5 billion large varieties of domestic 3abo sugar tablets will soon be approved.

The new 4 generic drug "Acapo Sugar Tablet" (acceptance number: CYHS1900124) is in a "in-approval" state and is expected to be approved in the near future;(Source: NMPA) Domestic market three-tieraabo sugar is an alpha-glycoside enzyme inhibitor, the original research manufacturer is Bayer, Germany, in September 1999 was approved by NMPA listed, the product is called by sugaras a new type of oral anti-sugar drug, acapo sugar in the intestine can competitively inhibit glucosin hydrolysis enzyme, inhibit starch decomposition into glucose, and thus reduce the absorption of glucose in the intestine, reduce post-meal high blood sugarbecause acapo sugar mainly by inhibiting amylase to reduce the absorption of glucose, more suitable for rice, pasta and other carbohydrate-based Asian population, so the domestic sales situation is much better than the European and American marketsat present, the domestic Acapo sugar preparation approval has the original research Bayer, East China, Green Leaf Pharmaceuticals and Beijing Fuyuan Pharmaceutical (formerly Beijing Wansheng Pharmaceutical) 4, of which Bayer, East China, Beijing Fuyuan is a tablet, Green Leaf Pharmaceuticals as a capsule, East China medicine Akabo sugar first imitation was approved in 2002, the commodity name cabopin, specifications of 50mg, 100mg;East China Pharmaceuticals (50mg, 100mg), Green Leaf Pharmaceuticals (50mg) and Beijing Fuyuan (50mg) all passed consistency evaluationAccording to CmH data, in 2019, domestic sales of Acapo sugar reached 7,568 million yuan, of which, the original Bayer market share of about 60%, East China Pharmaceuticals more than 30%, the remaining green leaf pharmaceutical capsule dosage formthe 2017 edition of the health insurance catalog Acapo sugar from Class B to Class A, import substitution acceleratedaccording to industry sources, in 2019, East China medicine Acapo sugar tablet sales revenue is expected to exceed 3 billion yuan, year-on-year growth rate of 30%, has been the domestic market share of the first domestic oral sugar-lowering drugs(data source: Zhongkang CMH) East China Pharmaceutical Collection lost bid january 20, 2020, East China Pharmaceuticals announced that wholly-owned subsidiary of China east China's products Acapo sugar tablets (commodity name: Caboping) in the second batch of national organization drug centralized procurement due to price factors failed to win the bidannouncement shows that on January 17, China and east China have participated in the second national drug collection through acapo sugar tablets, a product for the evaluation of generic drug quality and efficacy consistencyafter the joint procurement office opened bids and evaluated bids according to the rules, china-U.SEast China Acapo sugar tablets this time due to price factors failed to win the bid(Source: Giant Tide Information Network) According to the previous collection of tenders, China east China, Bayer, Green Leaf Pharmaceuticals and Beijing Fuyuan participated in the bidding, four quotations are 13.96 yuan, 9.6 yuan, 5.42 yuan and 12.98 yuan, specifications are 50 mg /30 tablets (grain)based on the price, Bayer, Green Leaf bidEast China Pharmaceuticals' revenue in 2019 will reach about 35.446 billion yuan, of which sales from Acapo sugar account for about 9% of total revenue East China Pharmaceuticals was affected by the loss of bids, the market value once evaporated 7 billion yuan market competition CDE official website shows that the current acapo sugar overall competition is very fierce, in addition to 4 preparations have been listed, there are more than 30 enterprises in the research state of which Acapo sugar tablets, stone medicine, Haizheng, Qianjin and other pharmaceutical companies in the listing application; (Source: CDE)